Q-omics provides the consensus-scored PROSER3 profile across patient tissues and cancer cell-line models. PROSER3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PROSER3 is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, PROSER3 RNA expression shows 20,393 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where PROSER3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROSER3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROSER3 survival associations across molecular data types. PROSER3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROSER3 RNA expression–survival associations across cancer types. High PROSER3 expression shows unfavorable associations in KIRC, MESO and CESC, but favorable associations in HNSC, UCS and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PROSER3 RNA expression.
This table summarizes PROSER3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PROSER3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROSER3 shows higher tumor expression in KIRP, HNSC, COAD, LIHC, BLCA and KIRC. The KIRP box plot shows higher PROSER3 RNA expression in tumor versus normal tissue (log2 FC = +0.833, t-test p < 0.001).
This table shows molecular features associated with PROSER3 in patient tissues and cancer cell lines. In patient samples, PROSER3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PROSER3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
